University of Kentucky Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA.
Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34. doi: 10.1517/17425255.2012.660918. Epub 2012 Feb 15.
Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED-SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder.
This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED-SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies.
Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED-SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
抗癫痫药(AED)和第二代抗精神病药(SGAP)之间会发生药代动力学和药效学药物相互作用(DI)。一些 AED 和 SGAP 的药效学机制尚未得到充分理解。AED-SGAP 联合用药用于治疗合并疾病或提高疗效,特别是在双相情感障碍中。
本文全面回顾了抗癫痫药和第二代抗精神病药之间的相互作用。作者涵盖了 AED-SGAP 药代动力学 DI 研究、最新药物药代动力学以及有限的药效学 DI 研究。
剂量校正因子和测量 SGAP 水平有助于补偿卡马西平、苯妥英、苯巴比妥和扑米酮的诱导特性。需要进一步研究来确定以下联合用药的临床相关性:i)AED 强诱导剂与氨磺必利、阿塞那平、依洛哌酮、鲁拉西酮和帕利哌酮;ii)丙戊酸与阿立哌唑、阿塞那平、氯氮平、奥氮平;iii)高剂量的奥卡西平(≥ 1500mg/天)或托吡酯(≥ 400mg/天)与阿立哌唑、鲁拉西酮、喹硫平、利培酮、阿塞那平和奥氮平。两种药效学 DI 有益:i)丙戊酸-SGAP 联合用药可能在双相情感障碍中有相加作用,ii)将托吡酯或佐米曲普坦与 SGAP 联合使用可能会减轻体重增加。三种常见但会降低安全性的药效学 DI 包括镇静、体重增加和吞咽困难。少数 AED-SGAP 联合用药可能会增加骨质疏松症或恶心的风险。三种潜在致命但罕见的药效学 DI 包括胰腺炎、粒细胞缺乏症/白细胞减少症和中暑。作者认为,药物管理局和制药公司、使用这些联合用药的临床医生、具有荟萃分析专业知识的研究人员、资助机构、药物流行病学学家和 DI 药理学家需要合作,才能推动这一领域的进一步发展。